Provencio, Mariano <br/><br/>
Consolidation treatment with Yttrium-90 ibritumomab tiuxetan after new induction regimen in patients with intermediate- and high-risk follicular lymphoma according to the follicular lymphoma international prognostic index: a multicenter, prospective phase II trial of the Spanish Lymphoma Oncology Group.  [electronic resource] 

 -  Leukemia & lymphoma  Jan 2014 
 - 51-5 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>1029-2403 
<br/><br/><label>Standard No.: </label>10.3109/10428194.2013.790544  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Murine-Derived--adverse effects<br/>Antineoplastic Agents--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Consolidation Chemotherapy<br/>Cyclophosphamide--adverse effects<br/>Doxorubicin--adverse effects<br/>Female<br/>Humans<br/>Induction Chemotherapy<br/>Lymphoma, Follicular--drug therapy<br/>Male<br/>Medication Adherence<br/>Middle Aged<br/>Neoplasm Grading<br/>Neoplasm Staging<br/>Prednisone--adverse effects<br/>Prognosis<br/>Risk Factors<br/>Rituximab<br/>Treatment Outcome<br/>Vincristine--adverse effects